At present, several sodium-glucose cotransporter 2 (SGLT2) inhibitors, which were initially developed as glucose-lowering agents for type 2 diabetes, have been shown promising benefits to reduce the risk of hospitalization for HF (HHF) and cardiovascular death regardless of the presence or absence of diabetes (8, 9). The gene discussed is SLC5A2; the disease is hydrops fetalis.